Difference between revisions of "Rheumatoid arthritis"

From Aging Chart
Jump to: navigation, search
(Autoloading by CXLParser)
(Autoloading by CXLParser)
 
Line 162: Line 162:
 
(.//.)<html><!--Pop-up for: High risk of cardiovascular disease !Pop-up-->
 
(.//.)<html><!--Pop-up for: High risk of cardiovascular disease !Pop-up-->
 
<div class="1J0WP0D9G-8VRF9M-5Z4" style="display:none;">
 
<div class="1J0WP0D9G-8VRF9M-5Z4" style="display:none;">
 +
  
  
Line 173: Line 174:
 
</div>(...)<!--Pop-up for: Insulin signaling in synovial fibroblasts !Pop-up-->
 
</div>(...)<!--Pop-up for: Insulin signaling in synovial fibroblasts !Pop-up-->
 
<div class="1J0WNQFQK-1YQ7DG3-5RS" style="display:none;">
 
<div class="1J0WNQFQK-1YQ7DG3-5RS" style="display:none;">
 +
  
  
Line 184: Line 186:
 
</div>(...)<!--Pop-up for: Autoimmunity !Pop-up-->
 
</div>(...)<!--Pop-up for: Autoimmunity !Pop-up-->
 
<div class="1J0WPCPNR-1DNMP0B-6HJ" style="display:none;">
 
<div class="1J0WPCPNR-1DNMP0B-6HJ" style="display:none;">
 +
  
  
Line 195: Line 198:
 
</div>(...)<!--Pop-up for: Metalloproteinases !Pop-up-->
 
</div>(...)<!--Pop-up for: Metalloproteinases !Pop-up-->
 
<div class="1J0WR1JHK-24MTFTZ-7PV" style="display:none;">
 
<div class="1J0WR1JHK-24MTFTZ-7PV" style="display:none;">
 +
  
  
Line 206: Line 210:
 
</div>(...)<!--Pop-up for: C-reactive protein  In blood plasma !Pop-up-->
 
</div>(...)<!--Pop-up for: C-reactive protein  In blood plasma !Pop-up-->
 
<div class="1J0WR2P5M-2DKG818-7R3" style="display:none;">
 
<div class="1J0WR2P5M-2DKG818-7R3" style="display:none;">
 +
  
  
Line 217: Line 222:
 
</div>(...)<!--Pop-up for: Inflammatory  Mediator TNF-a !Pop-up-->
 
</div>(...)<!--Pop-up for: Inflammatory  Mediator TNF-a !Pop-up-->
 
<div class="1J0WPVF9Y-129WRW6-6XV" style="display:none;">
 
<div class="1J0WPVF9Y-129WRW6-6XV" style="display:none;">
 +
  
  
Line 228: Line 234:
 
</div>(...)<!--Pop-up for: Swelling !Pop-up-->
 
</div>(...)<!--Pop-up for: Swelling !Pop-up-->
 
<div class="1J0WN2YHR-LWR2JM-5JB" style="display:none;">
 
<div class="1J0WN2YHR-LWR2JM-5JB" style="display:none;">
 +
  
  
Line 239: Line 246:
 
</div>(...)<!--Pop-up for: Expression of  Chemoattractants and cytokines  (IL-16, RANTES) !Pop-up-->
 
</div>(...)<!--Pop-up for: Expression of  Chemoattractants and cytokines  (IL-16, RANTES) !Pop-up-->
 
<div class="1J0WQBBC5-FTKL08-754" style="display:none;">
 
<div class="1J0WQBBC5-FTKL08-754" style="display:none;">
 +
  
  
Line 250: Line 258:
 
</div>(...)<!--Pop-up for: Chronic inflammation of synovial membrane !Pop-up-->
 
</div>(...)<!--Pop-up for: Chronic inflammation of synovial membrane !Pop-up-->
 
<div class="1J0WN196D-11Y03MT-5GP" style="display:none;">
 
<div class="1J0WN196D-11Y03MT-5GP" style="display:none;">
 +
  
  
Line 261: Line 270:
 
</div>(...)<!--Pop-up for: Endothelial growth factor !Pop-up-->
 
</div>(...)<!--Pop-up for: Endothelial growth factor !Pop-up-->
 
<div class="1J0WR5ZB1-1N5Q0C1-7SC" style="display:none;">
 
<div class="1J0WR5ZB1-1N5Q0C1-7SC" style="display:none;">
 +
  
  
Line 272: Line 282:
 
</div>(...)<!--Pop-up for: Pain !Pop-up-->
 
</div>(...)<!--Pop-up for: Pain !Pop-up-->
 
<div class="1N9D28TJG-1TK199N-1BLC" style="display:none;">
 
<div class="1N9D28TJG-1TK199N-1BLC" style="display:none;">
 +
  
  
Line 283: Line 294:
 
</div>(...)<!--Pop-up for: Insulin-like growth factor receptor IGF-1R !Pop-up-->
 
</div>(...)<!--Pop-up for: Insulin-like growth factor receptor IGF-1R !Pop-up-->
 
<div class="1J0WP6NLN-1DXP6QM-66Z" style="display:none;">
 
<div class="1J0WP6NLN-1DXP6QM-66Z" style="display:none;">
 +
  
  
Line 294: Line 306:
 
</div>(...)<!--Pop-up for: Joint infiltration  By macrophages !Pop-up-->
 
</div>(...)<!--Pop-up for: Joint infiltration  By macrophages !Pop-up-->
 
<div class="1J0WPRBFK-20JRB5M-6T2" style="display:none;">
 
<div class="1J0WPRBFK-20JRB5M-6T2" style="display:none;">
 +
  
  
Line 305: Line 318:
 
</div>(...)<!--Pop-up for: T-lymphocytes !Pop-up-->
 
</div>(...)<!--Pop-up for: T-lymphocytes !Pop-up-->
 
<div class="1J0WNR6TX-NWXB15-5T6" style="display:none;">
 
<div class="1J0WNR6TX-NWXB15-5T6" style="display:none;">
 +
  
  
Line 316: Line 330:
 
</div>(...)<!--Pop-up for: Disturbance of joint mobility !Pop-up-->
 
</div>(...)<!--Pop-up for: Disturbance of joint mobility !Pop-up-->
 
<div class="1J0WN57FC-SM7666-5L0" style="display:none;">
 
<div class="1J0WN57FC-SM7666-5L0" style="display:none;">
 +
  
  
Line 327: Line 342:
 
</div>(...)<!--Pop-up for: Rheumatoid arthritis !Pop-up-->
 
</div>(...)<!--Pop-up for: Rheumatoid arthritis !Pop-up-->
 
<div class="1J0WMZTR6-1JDV0XR-5FN" style="display:none;">
 
<div class="1J0WMZTR6-1JDV0XR-5FN" style="display:none;">
 +
  
  
Line 338: Line 354:
 
</div>(...)<!--Pop-up for: Stiffness in joints !Pop-up-->
 
</div>(...)<!--Pop-up for: Stiffness in joints !Pop-up-->
 
<div class="1N9D291R5-1ZP5XWC-1BLH" style="display:none;">
 
<div class="1N9D291R5-1ZP5XWC-1BLH" style="display:none;">
 +
  
  

Latest revision as of 09:26, 2 August 2015

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Rheumatoid arthritis

Rheumatoid arthritis (RA) is a chronic inflammatory disease that manifests predominantly as synovial inflammation leading to cartilage damage and destruction of the joint infrastructure. Although the joint symptomatology is eventually dominant, the disease is preceded by immune abnormalities that are not joint-specific, but systemic and already apparent many years before onset of the disease. Rheumatoid arthritis (RA) is a symmetric polyarticular arthritis and in addition to inflammation in the synovium, which is the joint lining, the aggressive front of tissue called pannus invades and destroys local articular structures. The synovium is normally a relatively acellular structure with a delicate intimal lining.

Insulin and insulin-like growth factors (IGFs) are polypeptide hormones with high sequence similarity. Insulin has extensive metabolic and mitogenic effects that regulate utilization of carbohydrates, while IGF-1 is an important growth factor involved in cell growth, differentiation, and cell survival. In addition to the canonical IR/IGF-1R signaling pathways, ligation of IGF-1R may lead to cross-talk and induce signaling via receptors belonging to the cytokine receptor family. IGF-1 promotes survival and delays apoptosis of human neutrophils and T lymphocytes, both of which contribute to the pathologic development of inflammatory diseases such as RA.

The age relationship of RA is different from that of organ-specific autoimmune diseases, such as diabetes mellitus or systemic lupus erythematosus that peak earlier in life. The age-inappropriate accelerated telomeric erosion found in lymphocytes of patients with RA could be caused by several mechanisms, either acting alone or in concert. Telomeric erosion could reflect an increased proliferative history of lymphocytes or their precursor cells, or be caused by defective telomerase expression or activity. Alternatively, telomeric shortening could be the result of excessive DNA damage rather than replication-induced telomeric loss. Data on patients with RA indicate that all three of these different mechanisms play a role.